Pancreatic Enzyme Replacement Therapy
The question
To ask the Secretary of State for Health and Social Care, what steps he is taking to increase the supply of Creon.
Answered by Karin Smyth
The Department is in regular discussion with the supplier of Creon on the latest stock availability and the actions that are being taken to mitigate the supply issue that is affecting the whole of the United Kingdom. Through these discussions we have managed to secure additional volumes of Creon for 2025 for the UK. We continue to work with all suppliers of pancreatic enzyme replacement therapy (PERT) to understand what more can be done to add further resilience to the market. The Department has also worked with specialist importers who have sourced unlicensed stock to assist in covering the remaining gap in the market.
In the longer term, the Department has had interest from non-UK suppliers of PERT wishing to bring their products to the UK and, along with colleagues in the Medicine and Healthcare products Regulatory Agency, we are working with these potential suppliers; if authorised these products could further diversify and strengthen the market.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →